Back to search

Peptide record

TPDB24049

Pep27anal2 Antibacterial Anticancer Hemolysis Toxicity standard
27 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB24049
Pep27anal2
Antibacterial Anticancer Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 27-aa standard natural multi-activity (Antibacterial, Anticancer, Hemolysis, and other sources) peptide sequence curated from Peptipedia, AntiCP 2.0, CancerPPD 2.0, and other sources, with an available 3D structural model.
Sequence
MWKWFHNVLSWWWLLADKRPARDYNRK
Physicochemical Analysis
C173H244N48O36S1
CEQGIT
W
3604.20
10.87
7
2
14
+4
-3.26
-0.989
61.48
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
28990
804.34
4
Residue Composition
number
2
A
3
R
2
N
2
D
0
C
0
E
0
Q
0
G
1
H
0
I
3
L
3
K
1
M
1
F
1
P
1
S
0
T
5
W
1
Y
1
V
Amino Acid Distribution
A: 2 R: 3 N: 2 D: 2 C: 0 E: 0 Q: 0 G: 0 H: 1 I: 0 L: 3 K: 3 M: 1 F: 1 P: 1 S: 1 T: 0 W: 5 Y: 1 V: 1
Chemical Descriptors
27
C173H244N48O36S1
3604.20
10.87
+4
-3.26
-0.989
Free
L
Linear
Free
Anticancer
S. pneumoniae
Evidence Records 9 records
Evidence 1 Activity

Activity

IC50
IC50= 29 µM
Anticancer
29 µM

Target

Leukemia Cancer
AML-2
Blood

Assay & Model

MTT/MTS assay
22.5-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50= 20 µM
Anticancer
20 µM

Target

Leukemia Cancer
HL-60
Blood

Assay & Model

MTT/MTS assay
22.5-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 3 Activity

Activity

IC50
IC50= 23 µM
Anticancer
23 µM

Target

Blood Cancer
Jurkat
Blood

Assay & Model

MTT/MTS assay
22.5-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 4 Activity

Activity

IC50
IC50= 25 µM
Anticancer
25 µM

Target

Gastric Cancer
SNU-601
Stomach

Assay & Model

MTT/MTS assay
22.5-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 5 Activity

Activity

IC50
IC50= <10 µM
Anticancer
<10 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
22.5-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 6 Activity

Activity

0% Hemolysis
Toxicity
6.25 µM
Hemolytic Cytotoxic
0% Hemolysis | 6.25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Functional and structural characteristics of anticancer peptide Pep27 analogues. | Cancer Cell Int | 2005
Evidence 7 Activity

Activity

18% Hemolysis
Toxicity
12.5 µM
Hemolytic Cytotoxic
18% Hemolysis | 12.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Functional and structural characteristics of anticancer peptide Pep27 analogues. | Cancer Cell Int | 2005
Evidence 8 Activity

Activity

% Hemolysis
Toxicity
18 %
Hemolytic Cytotoxic
Hemolytic_activity: Human RBCs(18% hemolysis at 12.5 µM), Human RBCs(0% hemolysis at 0.19 µM, 0.39 µM, 0.78 µM, 1.56 µM, 3.12 µM, 6.25 µM) | Cytotoxicity: Not available

Target

erythrocytes

Source & Reference

NA
DRAMP
Cancer Cell Int. 2005 Jul 11 5:21.
Evidence 9 Hemolysis

Source & Reference

HemoPI PD_Hemolysis
PD_Hemolysis